UY27499A1 - Anticuerpos humanos que se unen a mn y tiene actividad neutralizante de la adhesión celular - Google Patents
Anticuerpos humanos que se unen a mn y tiene actividad neutralizante de la adhesión celularInfo
- Publication number
- UY27499A1 UY27499A1 UY27499A UY27499A UY27499A1 UY 27499 A1 UY27499 A1 UY 27499A1 UY 27499 A UY27499 A UY 27499A UY 27499 A UY27499 A UY 27499A UY 27499 A1 UY27499 A1 UY 27499A1
- Authority
- UY
- Uruguay
- Prior art keywords
- join
- antibodies
- human antibodies
- neutralizing activity
- cellular adhesion
- Prior art date
Links
- 230000001413 cellular effect Effects 0.000 title 1
- 230000003472 neutralizing effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000011144 upstream manufacturing Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34365701P | 2001-10-18 | 2001-10-18 | |
| US37771602P | 2002-05-02 | 2002-05-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY27499A1 true UY27499A1 (es) | 2003-05-30 |
Family
ID=26993561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY27499A UY27499A1 (es) | 2001-10-18 | 2002-10-17 | Anticuerpos humanos que se unen a mn y tiene actividad neutralizante de la adhesión celular |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7462696B2 (enExample) |
| EP (1) | EP1438339A4 (enExample) |
| JP (2) | JP2005528884A (enExample) |
| KR (1) | KR20050037478A (enExample) |
| CN (1) | CN1606569A (enExample) |
| AR (1) | AR036833A1 (enExample) |
| BR (1) | BR0213968A (enExample) |
| CA (1) | CA2463943A1 (enExample) |
| CO (1) | CO5370684A1 (enExample) |
| DO (1) | DOP2002000494A (enExample) |
| HU (1) | HUP0600335A2 (enExample) |
| IL (1) | IL161411A0 (enExample) |
| MX (1) | MXPA04003508A (enExample) |
| PE (1) | PE20030473A1 (enExample) |
| PL (1) | PL374304A1 (enExample) |
| RU (1) | RU2317998C2 (enExample) |
| UY (1) | UY27499A1 (enExample) |
| WO (1) | WO2003033674A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US7504364B2 (en) | 2002-03-01 | 2009-03-17 | Receptors Llc | Methods of making arrays and artificial receptors |
| US20090162382A1 (en) * | 2002-03-01 | 2009-06-25 | Bernett Matthew J | Optimized ca9 antibodies and methods of using the same |
| US7469076B2 (en) | 2003-09-03 | 2008-12-23 | Receptors Llc | Sensors employing combinatorial artificial receptors |
| WO2005003326A2 (en) | 2003-03-28 | 2005-01-13 | Receptors Llc. | Artificial receptors including reversibly immobilized building blocks and methods |
| WO2004075855A2 (en) * | 2003-02-26 | 2004-09-10 | Biomed Solutions, Llc | Process for in vivo treatment of specific biological targets in bodily fluid |
| EP1664778A2 (en) * | 2003-09-03 | 2006-06-07 | Receptors LLC | Nanodevices employing combinatorial artificial receptors |
| WO2006028930A2 (en) | 2004-09-03 | 2006-03-16 | Receptors Llc | Combinatorial artificial receptors including tether building blocks on scaffolds |
| WO2006029383A2 (en) | 2004-09-11 | 2006-03-16 | Receptors Llc | Combinatorial artificial receptors including peptide building blocks |
| DOP2006000277A (es) * | 2005-12-12 | 2007-08-31 | Bayer Pharmaceuticals Corp | Anticuerpos anti mn y métodos para su utilización |
| US20140273033A1 (en) * | 2007-04-12 | 2014-09-18 | Universiteit Hasselt | Biomarkers for multiple sclerosis |
| JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
| CN102112154B (zh) * | 2008-05-30 | 2013-10-30 | 埃克斯生物科技公司 | 白细胞介素-1α抗体及使用方法 |
| AU2013328580B2 (en) | 2012-10-12 | 2016-01-21 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| MX362970B (es) | 2013-03-13 | 2019-02-28 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
| US11215615B2 (en) * | 2014-04-03 | 2022-01-04 | AllerGenis LLC | Peptides, reagents and methods for detecting food allergy |
| CN106687141A (zh) | 2014-09-10 | 2017-05-17 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其缀合物 |
| WO2018069289A1 (en) | 2016-10-11 | 2018-04-19 | Medimmune Limited | Antibody-drug conjugates with immune-mediated therapy agents |
| SG11202010469QA (en) | 2018-05-23 | 2020-11-27 | Adc Therapeutics Sa | Molecular adjuvant |
| WO2022079211A1 (en) | 2020-10-16 | 2022-04-21 | Adc Therapeutics Sa | Glycoconjugates |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| EP4426727A2 (en) | 2021-11-03 | 2024-09-11 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| ATE356869T1 (de) * | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
| US6297051B1 (en) * | 1997-01-24 | 2001-10-02 | Institute Of Virology, Slovak Academy Of Sciences | MN gene and protein |
| WO1995034650A2 (en) * | 1994-06-15 | 1995-12-21 | Ciba Corning Diagnostics Corp. | Mn gene and protein |
| AU758957C (en) * | 1998-10-23 | 2004-08-12 | Institute Of Virology Of The Slovak Academy Of Sciences | MN gene and protein |
| US6689744B2 (en) * | 2000-09-22 | 2004-02-10 | Genentech, Inc. | Notch receptor agonists and uses |
-
2002
- 2002-10-16 AR ARP020103877A patent/AR036833A1/es unknown
- 2002-10-17 DO DO2002000494A patent/DOP2002000494A/es unknown
- 2002-10-17 UY UY27499A patent/UY27499A1/es not_active Application Discontinuation
- 2002-10-18 CN CNA028254880A patent/CN1606569A/zh active Pending
- 2002-10-18 HU HU0600335A patent/HUP0600335A2/hu unknown
- 2002-10-18 MX MXPA04003508A patent/MXPA04003508A/es not_active Application Discontinuation
- 2002-10-18 PE PE2002001031A patent/PE20030473A1/es not_active Application Discontinuation
- 2002-10-18 JP JP2003536404A patent/JP2005528884A/ja active Pending
- 2002-10-18 CO CO02094163A patent/CO5370684A1/es unknown
- 2002-10-18 BR BR0213968-5A patent/BR0213968A/pt not_active IP Right Cessation
- 2002-10-18 KR KR1020047005716A patent/KR20050037478A/ko not_active Withdrawn
- 2002-10-18 EP EP02786449A patent/EP1438339A4/en not_active Withdrawn
- 2002-10-18 CA CA002463943A patent/CA2463943A1/en not_active Abandoned
- 2002-10-18 WO PCT/US2002/033470 patent/WO2003033674A2/en not_active Ceased
- 2002-10-18 RU RU2004115112/13A patent/RU2317998C2/ru not_active IP Right Cessation
- 2002-10-18 US US10/273,541 patent/US7462696B2/en not_active Expired - Fee Related
- 2002-10-18 PL PL02374304A patent/PL374304A1/xx not_active Application Discontinuation
- 2002-10-18 IL IL16141102A patent/IL161411A0/xx unknown
-
2008
- 2008-12-08 US US12/330,504 patent/US20100240100A1/en not_active Abandoned
-
2010
- 2010-02-01 JP JP2010020670A patent/JP2010260845A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2463943A1 (en) | 2003-04-24 |
| PE20030473A1 (es) | 2003-06-26 |
| HUP0600335A2 (en) | 2006-08-28 |
| BR0213968A (pt) | 2005-05-10 |
| JP2005528884A (ja) | 2005-09-29 |
| EP1438339A4 (en) | 2008-08-27 |
| US7462696B2 (en) | 2008-12-09 |
| DOP2002000494A (es) | 2004-05-31 |
| PL374304A1 (en) | 2005-10-03 |
| MXPA04003508A (es) | 2004-07-22 |
| WO2003033674A3 (en) | 2003-08-21 |
| US20100240100A1 (en) | 2010-09-23 |
| US20030077277A1 (en) | 2003-04-24 |
| CN1606569A (zh) | 2005-04-13 |
| JP2010260845A (ja) | 2010-11-18 |
| EP1438339A2 (en) | 2004-07-21 |
| KR20050037478A (ko) | 2005-04-22 |
| RU2004115112A (ru) | 2005-04-27 |
| RU2317998C2 (ru) | 2008-02-27 |
| AR036833A1 (es) | 2004-10-06 |
| CO5370684A1 (es) | 2004-02-27 |
| IL161411A0 (en) | 2004-09-27 |
| WO2003033674A2 (en) | 2003-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY27499A1 (es) | Anticuerpos humanos que se unen a mn y tiene actividad neutralizante de la adhesión celular | |
| CY1123400T1 (el) | Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
| CY1113243T1 (el) | Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4 | |
| CY1121173T1 (el) | Μορια αντισωματων εξειδικευμενα για τον ανθρωπινο παραγοντα νεκρωσης των ογκων αλφα, και χρηση αυτων | |
| CY1120070T1 (el) | Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους | |
| PE20050712A1 (es) | Anticuerpos rg1 | |
| BRPI0314038B8 (pt) | anticorpo humano isolado, molécula de ácido nucleico isolada, vetor, uso de um anticorpo, e, composição farmacêutica | |
| CY1112507T1 (el) | Μορια αντισωματος που εχουν ειδικοτητα για την ανθρωπινη ιl-1β | |
| BR9710811A (pt) | Fragmentos de liga-Æo de antigeno que detecta especificamente c-lulas cancerigenas nucleotideos que codificam os fragmentos e o seu uso para a profilaxia e detec-Æo de c-nceres | |
| CY1118443T1 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
| AR038568A1 (es) | Anticuerpos anti-a beta y su uso | |
| AR047729A1 (es) | Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe) | |
| CY1107628T1 (el) | Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων | |
| PE20071055A1 (es) | Anticuerpos anti mn | |
| DE69617440D1 (de) | Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen | |
| WO2002083171A3 (en) | Cancer treatment by using fap-alpha specific antibodies | |
| CL2008003323A1 (es) | Uso de un anticuerpo que se une a cd20 porque sirve para preparar un medicamento para tratar enfermedades autoinmunes; acido nucleico que codifica una proteina cd20 de mono cynomolgus; vector que lo comprende; celula huesped y polipeptido cd20 de mono cynomolgus (div.sol.no.2639-03). | |
| ECSP088636A (es) | Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos, y métodos de uso en la terapia de cáncer | |
| BR112021024544A2 (pt) | Anticorpo monoclonal anti-ceacam5 e método de preparação do mesmo e uso do mesmo | |
| PE20221326A1 (es) | Anticuerpos anti-mertk y metodos de uso de los mismos | |
| DK1572087T3 (da) | Antistoffer med cancerantigen TMEFF2 og anvendelser deraf | |
| ATE366746T1 (de) | Gegen das semp1-protein gerichtete antikörper, verfahren zu deren herstellung, und deren anwendungen | |
| CO2022006909A2 (es) | Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso | |
| ATE248189T1 (de) | Antikörper gegen vasp (vasodilator-stimulated phosphoprotein), hybridomzellen für deren gewinnung, und deren verwendung | |
| BR0116763A (pt) | Anticorpos humanos especìficos para terapia seletiva do c ncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20151110 |